Is the fat anterior to the psoas muscle (psoas major) below the lower pole of the kidney, specifically the perirenal fat (fat surrounding the kidney), an uncommon location for lymph node metastasis in renal cell carcinoma (kidney cancer)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Lymph node metastasis in the fat anterior to the psoas muscle below the lower pole of the kidney, specifically the perirenal fat, is not an uncommon location for metastasis in renal cell carcinoma (kidney cancer). This is because renal lymphatic drainage commonly follows the renal veins to the para-aortic and paracaval lymph nodes, which can include nodes in this anterior parapsoas location 1. When evaluating for potential metastatic spread of kidney cancer, radiologists and oncologists typically assess multiple lymphatic drainage pathways, including hilar, paracaval, para-aortic, and interaortocaval regions.

Key Points to Consider

  • The location of the primary tumor within the kidney influences the lymphatic spread pattern, with upper pole tumors often draining to paracaval or interaortocaval nodes, while lower pole tumors may drain to para-aortic nodes including those anterior to the psoas muscle 1.
  • The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with ccRCC and nonclear cell RCC (nccRCC), emphasizing the importance of understanding lymphatic drainage patterns for proper staging and surgical planning 1.
  • Renal cell carcinoma primarily metastasizes to the lung, bone, liver, lymph nodes, adrenal gland, and brain, with lymph nodes being a common site for metastasis 1.

Clinical Implications

  • Clinicians should be aware of the potential for lymph node metastasis in the anterior parapsoas region, particularly when evaluating patients with renal cell carcinoma.
  • Accurate staging and surgical planning rely on a thorough understanding of lymphatic drainage patterns and potential sites for metastasis.
  • The fat anterior to the psoas muscle below the lower pole of the kidney should be considered a potential site for lymph node metastasis in patients with kidney cancer, as it is not an uncommon location for metastasis 1.

From the Research

Lymph Node Metastasis in Renal Cell Carcinoma

  • The location of lymph node metastasis in renal cell carcinoma (RCC) can vary, with some studies suggesting that the fat anterior to the psoas muscle, specifically the perirenal fat, is not a common location for metastasis 2, 3.
  • However, other studies have found that lymph node metastasis can occur in the perirenal fat, although the frequency of this occurrence is not well established 4, 5.
  • The patterns of lymph node enlargement in patients with metastatic RCC have been studied, with one study finding that two-thirds of nodes exhibited a suprahilar, intra-aortocaval, and retro-aortocaval trend of lymph node enlargement 3.
  • Another study found that lymph node metastasis could be estimated in 188 out of 249 patients with RCC, with histologically confirmed lymph node metastasis classified as pN1 in 8 cases, pN2 in 7 cases, and pN3 in 5 cases 4.
  • The role of lymph node dissection in RCC is still a topic of debate, with some studies suggesting that it may provide improved staging or a therapeutic advantage, while others argue that it may not be necessary for all patients 6.

Perirenal Fat and Lymph Node Metastasis

  • The perirenal fat, which surrounds the kidney, is not typically considered a common location for lymph node metastasis in RCC 2, 3.
  • However, one study found that enlarged lymph nodes in the perirenal fat were diagnosed on preoperative scans in 43 patients, with 18 of these patients (42%) having histologically confirmed metastases 5.
  • The study also found that significant lymph node enlargement frequently may be caused by inflammatory changes, especially in the presence of tumor necrosis, rather than metastatic disease 5.

Related Questions

Does the fat anterior to the psoas muscle, located below the lower pole of the left kidney, lack lymph nodes and is it not a site for metastatic lymph nodes from renal (kidney) cancer?
Is the fat anterior to the psoas muscle, below the lower pole of the kidney, which is part of the perirenal (perirenal) fat, an uncommon location for lymph node metastasis in kidney cancer?
Is the fat anterior to the psoas (musculus psoas), below the lower pole of the left kidney, part of the lymphatic chain for renal (kidney) cancer?
Does the fat anterior to the psoas (major muscle in the lower back) below the lower pole of the left kidney contain lymph nodes, participate in the lymphatic chain for the kidneys, or serve as a location for metastatic lymph nodes from renal (kidney) cancer?
Is the fat anterior to the psoas muscle below the lower pole of the left kidney part of the lymphatic chain for kidney cancer lymph node metastasis?
How often should liver function tests (LFTs), including liver enzymes, be monitored when initiating fezolinetant (NK1 receptor antagonist) in a postmenopausal patient?
What is the recommended frequency for checking laboratory tests in patients taking Depakote (valproate)?
Is the fat anterior to the psoas muscle, below the lower pole of the kidney, typically considered perirenal or pararenal fat, and is it an uncommon site for lymph node metastasis in renal cell carcinoma (kidney cancer)?
What thyroid function tests should be measured after thyroidectomy (thyroid removal)?
Is the fat anterior to the psoas muscle, below the lower pole of the kidney, which is part of the perirenal (perirenal) fat, an uncommon location for lymph node metastasis in kidney cancer?
What is the treatment for IgG3 kappa (Immunoglobulin G3 kappa) glomerulonephritis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.